Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery

Marta Brambilla; Alessandro Parolari; Marina Camera; Susanna Colli; Sonia Eligini; Chiara Centenaro; Achille Anselmo; Francesco Alamanni; Elena Tremoli

doi:10.1160/TH09-07-0470

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(03): 516-524
DOI: 10.1160/TH09-07-0470

Theme Issue Article

Schattauer GmbH

Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery

Authors

Marta Brambilla

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy
Alessandro Parolari

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy

⁴Department of Cardiovascular Sciences, Università degli Studi di Milano, Milano, Italy
Marina Camera

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy

²Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy
Susanna Colli

²Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy
Sonia Eligini

²Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy
Chiara Centenaro

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy
Achille Anselmo

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy

³Department of Inflammation and Immunology, Istituto Clinico Humanitas, Rozzano, Milano, Italy
Francesco Alamanni

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy

⁴Department of Cardiovascular Sciences, Università degli Studi di Milano, Milano, Italy
Elena Tremoli

¹Centro Cardiologico Monzino, IRCCS, Milano, Italy

²Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy

Abstract

Summary

Early post-operative aspirin improves survival in patients undergoing coronary artery bypass graft (CABG). However, most patients do not benefit of aspirin after CABG, still remaining at risk of thrombotic events due to insufficient platelet inhibition, specifically via the thromboxane (TX) pathway. We evaluated the effect of two aspirin doses (100 or 325 mg daily, enteric coated formulations) on platelet function and TX biosynthesis in patients after CABG and assessed whether the incidence of residual platelet reactivity could be reduced by the higher dose. Fifty-six patients undergoing CABG were randomly assigned to 100 or 325 mg aspirin daily for five days in a prospective single-centre study. Treatment effect was assessed by measuring either platelet function (light-transmission aggregometry and point-of-care PFA-100^®) or TX biosynthesis in collagen-stimulated platelets, serum, urine, and in lipopolysaccharide (LPS)-cultured whole blood (WB). An insufficient TX inhibition was observed with 100 mg aspirin but not with the higher dose. The different effect of the two doses was, however, highlighted by either TX (platelet- or serum-derived) or by PFA-100^® but not by the other assays. In conclusion, early after CABG, the incidence of residual platelet activity was lower in patients who received 325 mg aspirin. Moreover, evidence was provided that different methods yield different results in the detection of aspirin resistance, rendering them not interchangeable.

Keywords

Aspirin - coronary surgery - platelet pharmacology - platelet aggregation - thromboxane

Full Text

References

References
1 Patrono C, Coller B, FitzGerald GA. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
2 Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081-1085.
3 Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186.
4 Armstrong PC, Truss NJ, Ali FY. et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008; 6: 1933-1943.
5 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
6 Patrono C, Baigent C, Hirsh J. et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.
7 Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
8 Gurbel PA, Becker RC, Mann KG. et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
9 Lordkipanidze M, Pharand C, Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
10 Hjemdahl P. Should we monitor platelet function during antiplatelet therapy?. Heart 2008; 94: 685-687.
11 Santilli F, Rocca B, De Cristofaro R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance“. J Am Coll Cardiol 2009; 53: 667-677.
12 Frelinger AL, Li Y, Linden MD. et al. Aspirin ‘resistance‘: role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035-2044.
13 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
14 Zimmermann N, Kurt M, Wenk A. et al. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?. Eur J Cardiothorac Surg 2005; 27: 606-610.
15 Parolari A, Camera M, Alamanni F. et al. Systemic inflammation after on-pump and off-pump coronary bypass surgery: a one-month follow-up. Ann Thorac Surg 2007; 84: 823-828.
16 Cattaneo M, Lecchi A, Zighetti ML. et al. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007; 92: 694-697.
17 Linnemann B, Schwonberg J, Mani H. et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677-683.
18 Patrignani P, Panara MR, Greco A. et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705-1712.
19 Pulcinelli FM, Riondino S, Celestini A. et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 3: 2784-2789.
20 Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-1211.
21 Cox D, Maree AO, Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-2158.
22 Hyde JA, Chinn JA, Graham TR. Platelets and cardiopulmonary bypass. Perfusion 1998; 13: 389-407.
23 Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-2152.
24 Ballotta A, Saleh HZ, El Baghdady HW. et al. Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007; 134: 132-138.
25 Evangelista V, Manarini S, Di Santo A. et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595.
26 Cornelissen J, Kirtland S, Lim E. et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost 2006; 95: 476-482.
27 Faraday N, Yanek LR, Mathias R. et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115: 2490-2496.
28 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
29 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
30 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-198.
31 Reny JL, De Moerloose P, Dauzat M. et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
32 Vejar M, Fragasso G, Hackett D. et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63: 163-168.
33 Cipollone F, Patrignani P, Greco A. et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109-1116.
34 Ohmori T, Yatomi Y, Nonaka T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4: 1271-1278.